A novel immunotherapeutic approach to treat cancer has also been developed using the CRISPR/Cas9 system by eliminating SIRP-α from macrophages, which improved their capacity to phagocytose cancer cells (Ray et al., 2018). Here, SIRPA is linked to cancer.